Opioid

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Retrieved on: 
Monday, January 22, 2024
Biomarker, Research, ACON, Diagnosis, Low back pain, Software as a service, CO, Algorithm, Spine, Division, Neurosurgery, Barrow Neurological Institute, Pain, Opioid, Magnetic resonance imaging, Education, United, Physician

BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.

Key Points: 
  • Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease.
  • Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain.
  • Uribe is a renowned neurosurgeon at one of the world’s leading neurological institutes, Barrow,” said Ryan Bond, Chief Strategy Officer of Aclarion.
  • For information about Nociscan use in Phoenix, please contact Aclarion at [email protected] .

NIDA Director to Deliver Keynote; Innovative Toxicology Research to Feature at 2024 ACMT Annual Scientific Meeting and Symposia in Washington, DC

Retrieved on: 
Wednesday, January 17, 2024
AACT, PFAS, Drug Safety, Occupational medicine, Addiction medicine, Research, ASM, Senior counsel, Health, Opioid, Antidote, Challenge, American Academy, Society, IST, Naloxone, Society of Toxicology, Public, Red, Omni Shoreham Hotel, Equity, Nursing, ASAM, Adolescence, American College, Physician

This five-day program will feature the latest advancements in medical toxicology research with numerous opportunities for networking and engagement.

Key Points: 
  • This five-day program will feature the latest advancements in medical toxicology research with numerous opportunities for networking and engagement.
  • Please note that registration for individual symposia is separate from the three-day main meeting.
  • The 2024 ACMT Annual Scientific Meeting main program will initiate on Friday, April 12.
  • Register now for the 2024 ACMT Annual Scientific Meeting and Symposia.

Pelago Expands C-Suite with Top Industry Talent to Position Company for Next Phase of Growth

Retrieved on: 
Thursday, January 25, 2024
Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Audio, Video, Managed Care, Mental Health, General Health, Hospitals, Other Technology, Software, Networks, Internet, Health, Mobile, Wireless, Online, Senior, Psychiatry, Capella University, Addiction, Fertility, Associate, Ziff Davis, Psychotherapy, Opioid, Fintech, Suds, Partnership, Business administration, Oxford University Press, Global Payments, University, Mentorship, Behavior, Bonnier, Acquisition, UCLA, National Geographic, Product management, Master of Business Administration, TSYS, New Harbinger Publications, Cognitive behavioral therapy, Marketing, Dun & Bradstreet, Tobacco, Offers.com, Dun, Engineering, ROI, Management

Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.

Key Points: 
  • Additionally, Ed Daley has been promoted to Chief Commercial Officer, and Paige Swanepoel has been promoted to Chief Marketing Officer.
  • Dr. Glasner will oversee Pelago’s clinical research programs and ROI validation, and support product development from a clinical perspective.
  • His experience includes business planning, partnership development, and client growth and management as well as building and mentoring high performing teams.
  • Pelago is revolutionizing substance use management and leading the industry with its 3x ROI and 100% fees-at-risk business model, based on validated clinical outcomes and performance metrics.

New Virtue Recovery Drug & Alcohol Rehab Center Opens in Killeen, TX to Serve the Local Community

Retrieved on: 
Monday, January 29, 2024
Ageing, Drug, Hope, Fentanyl, Substance Abuse, Binge drinking, Drinking, Law enforcement, NIBRS, Substance, Data collection, Education, Illegal drug trade, Statistics, Methamphetamine, Opioid, Human services, Prevalence, Government, Cultural diversity, Cocaine, Substance abuse

KILLEEN, Texas, Jan. 29, 2024 /PRNewswire-PRWeb/ -- Killeen, Texas, a vibrant city renowned for its military base (Ft Hood), aquatics park, and cultural diversity, has welcomed a crucial addition to its community resources - the recently opened Virtue Recovery Drug & Alcohol Rehab Center in Killeen. In the face of significant challenges related to drug and alcohol abuse, this state-of-the-art facility has emerged as a beacon of hope. Recent statistics have illuminated the extent of the issue, underscoring the pressing need for community awareness, prevention, and support, which are now being addressed by the center's comprehensive programs and dedicated staff.

Key Points: 
  • In response, the Killeen community has rallied together, welcoming the new Virtue Recovery Center in Killeen, a pivotal addition in their efforts to tackle these issues head-on.
  • KILLEEN, Texas, Jan. 29, 2024 /PRNewswire-PRWeb/ -- Killeen, Texas, a vibrant city renowned for its military base (Ft Hood), aquatics park, and cultural diversity, has welcomed a crucial addition to its community resources - the recently opened Virtue Recovery Drug & Alcohol Rehab Center in Killeen .
  • In the face of significant challenges related to drug and alcohol abuse, this state-of-the-art facility has emerged as a beacon of hope.
  • Our newly opened Drug & Alcohol Rehab Center is the beacon of hope Killeen needs to combat substance abuse effectively, in light of the concerning statistics.

The Honorable Patrick J. Kennedy Joins Healthsperien to Establish New Mental Health and Addiction Policy Practice

Retrieved on: 
Wednesday, January 24, 2024
DSM-IV codes, Hope, Commission, House, Addiction, Principal, Partner, Policy, Insurance, Louisiana House of Representatives, Mental health, Parity, Movement, Caregiver, Congress, Bell Trade Act, Opioid, Progress, Private sector, Act, Representative

WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Healthsperien, LLC, a leading national health care policy consulting firm, announced today that former US Representative Patrick J. Kennedy has been named as a Partner with the firm and will establish and lead a new national mental health and addiction policy practice. Rep. Kennedy will bring his decades of national leadership, advocacy, and expertise in mental health to advise a diverse array of clients, focusing on mental health and addiction, community-based services and supports, and the need for health system transformation.

Key Points: 
  • WASHINGTON, Jan. 24, 2024 /PRNewswire/ -- Healthsperien , LLC, a leading national health care policy consulting firm, announced today that former US Representative Patrick J. Kennedy has been named as a Partner with the firm and will establish and lead a new national mental health and addiction policy practice.
  • Rep. Kennedy will bring his decades of national leadership, advocacy, and expertise in mental health to advise a diverse array of clients, focusing on mental health and addiction, community-based services and supports, and the need for health system transformation.
  • Rep. Kennedy now brings his wealth of expertise to Healthsperien, where he will advance federal health policy to ensure quality care for those with mental health and addiction disorders.
  • "Representative Kennedy stands as a beacon of hope for transforming the national narrative on addiction and mental health.

Ibogaine By David Dardashti Analyzes Connections Between Physical and Emotional Pain

Retrieved on: 
Monday, January 15, 2024
Hydrocodone, Oxycodone, Fentanyl, Physical fitness, Communication, Opioid, Chronic pain, Ibogaine, Pain, Methadone, Buprenorphine/naloxone, Research, Brain, Nursing

While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.

Key Points: 
  • While opiates are commonly used to treat physical pain, they have been found to have a significant impact on emotional pain as well.
  • Research suggests that opiates enhance the production of opiate receptors, creating interconnected pathways that regulate both physical and emotional pain.
  • These drugs create interconnected pathways that regulate both emotional and physical pain, providing relief to individuals struggling with opioid addiction.
  • This not only helps individuals recover without having to undergo physical and emotional discomfort, but also stabilizes the brain and body, improving communication between physical and emotional pain.

AHN team performs region's first deep brain stimulation therapy to treat opioid addiction

Retrieved on: 
Saturday, January 13, 2024
AHN, Death, Obesity, Learning, Drug, Patient, Addiction, Research, DBS, Electrode, Multimedia, DSM-IV codes, Accident, Fentanyl, COVID, Xylazine, Parkinson's disease, IRB, Heroin, Deep brain stimulation, Food, AGH, Allegheny Health Network, Myenteric plexus, FDA, Opioid, Nucleus accumbens, Public, Addiction medicine, Institutional review board, Brain, Trial of the century, Physician, Pharmaceutical industry

PITTSBURGH, Jan. 13, 2024 /PRNewswire-PRWeb/ -- A multidisciplinary team of physicians at Allegheny Health Network (AHN) is among the first in the nation to safely utilize deep brain stimulation therapy (DBS) to treat a patient suffering from opioid addiction.

Key Points: 
  • PITTSBURGH, Jan. 13, 2024 /PRNewswire-PRWeb/ -- A multidisciplinary team of physicians at Allegheny Health Network (AHN) is among the first in the nation to safely utilize deep brain stimulation therapy (DBS) to treat a patient suffering from opioid addiction.
  • Led by principal investigator and AHN neurosurgeon Nestor D. Tomycz, MD, the AHN team announced this week that they have successfully implanted an deep brain stimulation (DBS) device in the brain of a 28-year-old New York man with treatment-resistant opioid addiction.
  • The procedure took place in December at AHN's Allegheny General Hospital, and the patient's ongoing therapy is part of an FDA-approved clinical study.
  • DBS for opioid-use disorder involves implanting bilateral electrode leads into an area of the brain called the nucleus accumbens – the brain's addiction and reward center.

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

Retrieved on: 
Wednesday, January 3, 2024
Opioid, Annual report, University, Research, CDMO, Importance, Traction, Scorpius, Pharmaceutical industry

Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.
  • Scorpius was selected due to its process development and large molecule manufacturing expertise, as well as its flexibility and dedication to customer service.
  • We are off to a strong start and look forward to expanding this relationship into additional programs in 2024 and beyond.
  • Scorpius offers a broad array analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the art facilities in San Antonio, TX.

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Extrapyramidal system, Opioid, ATC, Bowel obstruction, International, Syringe, European, Spinal cord, Injection, Nausea, Language, Brain, Abdominal pain, Laxative, Naltrexone, Morphine, Disorder, Chronic pain, Select, Anatomy, Medicine, Palliative care, Dialysis, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Medical Subject Headings, Peripheral, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Movement, Opioid, ATC, Pain, International, European, OIC, Spinal cord, Headache, Nausea, Language, Brain, Abdominal pain, Laxative, Cancer, Disorder, Tablet, Chronic pain, Select, Patient, Safety, Naloxone, Anatomy, Medicine, Bowel obstruction, Risk management, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised